UCB is selling its speciality generics unit Kremers Urban Pharmaceuticals to US group Lannett for $1.23 billion.
The deal includes Kremers’ commercial portfolio of 18 products and 11 applications pending at the FDA, as well as its 381,000-square foot state-of-the-art manufacturing facility in Seymour, Indiana.
The Belgian drugmaker said it plans to use proceeds from the divestiture to cut debt and increase its capacity for strategic investments, to further accelerate growth and/or strengthen its innovative medicines pipeline.
With unanimous backing from both UCB’s and Lannett’s boards of directors, the deal and is expected to close in the fourth quarter of this year, subject to customary closing conditions.
Osteoporosis drug beats Lilly’s Forteo
Meanwhile, UCB and Amgen said clinical data show that their experimental bone-building drug romosozumab was better at improving hip bone mineral density in postmenopausal women with osteoporosis than Lilly’s Forteo (teriparatide).
In the Phase III trial, around 436 postmenopausal women at high risk of fractures were switched from treatment with bisphosphonates (such as Merck & Co’s Fosamax) to either romosozumab or Forteo for 12 months.
Specific data were not revealed at this time, but the companies said the trial met its primary endpoint, with their drug showing a statistically significant improvement in bone density compared to Forteo.
By Selina McKee
Source: Pharma Times
After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.
Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.
UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.
